iRadimed (NASDAQ:IRMD) Posts Earnings Results

iRadimed (NASDAQ:IRMD) issued its quarterly earnings data on Tuesday. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.49 by $0.05, FiscalAI reports. The firm had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%. iRadimed updated its Q1 2026 guidance to 0.440-0.480 EPS and its FY 2026 guidance to 2.060-2.210 EPS.

Here are the key takeaways from iRadimed’s conference call:

• IRadimed posted its 18th consecutive quarter of record revenue—Q4 revenue of $22.7M (+17% YoY) and FY2025 revenue of $83.8M (+14%) with GAAP diluted EPS up 25% in Q4 and gross margins around 75–77%.
• Management expects the new 3870 MR IV pump to raise deal ASPs by 10–14% and drive a large replacement wave (targeting an additional ~1,000 domestic channel replacements/year), with a goal of selling north of 2,000 3870 channels domestically and approaching a $50M pump run rate (and a company run rate >$100M when add-ons are included).
• Early pilot feedback has been “very positive” after a December shipment of 23 systems, additional orders are on the books, and a broader sales release begins in April with initial shipments of ~100–130 3870 channels and expected booking ramp in H2 2026.
• Management expects gross margins to be roughly in line in H1 2026 with potential improvement in H2 as higher volumes and ASPs scale, while noting a transitional subscale period and active management of 3860 inventory as the company shifts to 3870 production.
• The balance sheet supports execution—year-end cash of $51.2M, FY operating cash flow of $24.9M and non-GAAP free cash flow of $16.5M after capex for a new Orlando facility.

iRadimed Price Performance

NASDAQ:IRMD traded down $1.83 during mid-day trading on Wednesday, hitting $103.32. 48,257 shares of the company’s stock were exchanged, compared to its average volume of 77,898. The company has a market cap of $1.31 billion, a PE ratio of 62.62 and a beta of 1.11. iRadimed has a one year low of $47.48 and a one year high of $107.90. The business has a fifty day moving average price of $98.08 and a 200 day moving average price of $83.43.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Monday, February 23rd will be given a dividend of $0.20 per share. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Monday, February 23rd. iRadimed’s payout ratio is 45.71%.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Reported record Q4 and full-year 2025 results with an EPS beat and revenue above consensus, showing healthy margins and profitability that support growth expectations. GlobeNewswire Release
• Positive Sentiment: Raised FY2026 EPS guidance to $2.060–2.210 and gave Q1 guidance slightly above or in line with Street estimates, signaling management confidence in continued revenue growth. Earnings Highlights
• Positive Sentiment: Announced a 17.6% increase in the regular quarterly cash dividend to $0.20 per share (ex-div Feb 23), returning cash to shareholders and reinforcing the company’s free-cash-flow profile. (Dividend details in press release.) Dividend & Results
• Positive Sentiment: Management projects a >$100M revenue run-rate in 2026 driven by ramp of the new 3870 MRI?compatible IV pump — a product catalyst that could materially expand TAM if adoption continues. Product Ramp Article
• Neutral Sentiment: Market/commentary pieces and an earnings preview provide additional context for investors but do not change fundamentals immediately. MSN Composite Rating
• Neutral Sentiment: Analyst previews and the full earnings call transcript are available for deeper diligence on margin drivers and commercialization plans. Benzinga Preview Earnings Transcript
• Negative Sentiment: Shares are trading lower today amid possible profit-taking after a run toward the 52?week high and despite the beat — lower intraday volume vs. average suggests cautious selling rather than broad panic.
• Negative Sentiment: Valuation appears rich (high forward P/E) relative to peers and recent growth expectations, which increases sensitivity to execution risk on the 3870 ramp and macro/healthcare spending cycles.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the sale, the chief executive officer directly owned 2,262,500 shares in the company, valued at approximately $227,720,625. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 55,000 shares of company stock worth $5,287,900. 36.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On iRadimed

Hedge funds have recently modified their holdings of the company. Cerity Partners LLC bought a new stake in shares of iRadimed in the 4th quarter worth about $261,000. Franklin Resources Inc. lifted its stake in shares of iRadimed by 39.5% in the 4th quarter. Franklin Resources Inc. now owns 15,828 shares of the medical equipment provider’s stock valued at $1,540,000 after purchasing an additional 4,480 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of iRadimed in the 4th quarter worth approximately $412,000. TD Asset Management Inc bought a new position in shares of iRadimed during the 4th quarter valued at approximately $389,000. Finally, Goldman Sachs Group Inc. raised its holdings in iRadimed by 37.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after buying an additional 55,426 shares during the period. 92.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on IRMD shares. Roth Mkm restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research report on Tuesday. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Lake Street Capital reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.